High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Bing Cui(Chinese Academy of Medical Sciences & Peking Union Medical College), Thomas J. Kipps(University of California San Diego), Laura Z. Rassenti(University of California San Diego), Jennifer R. Brown(Dana-Farber Cancer Institute), George F. Widhopf(University of California San Diego), Liguang Chen(University of California San Diego), Jian Yu(Queen's University), John G. Gribben(Queen Mary University of London), Emanuela M. Ghia(University of California San Diego), Kelly A. Frazer(University of California San Diego), Christopher DeBoever(University of California San Diego), R. Kanti(Hofstra University), Jeffrey A. Jones(The Ohio State University), Neil E. Kay(Mayo Clinic), William G. Wierda(The University of Texas MD Anderson Cancer Center), Donna Neuberg(Otsuka (Japan))
Cited by 144
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k